These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16305515)

  • 21. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
    Castillo SA; Hernandez JE; Brothers CH
    Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection.
    Dando TM; Scott LJ
    Drugs; 2005; 65(2):285-302. PubMed ID: 15631548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
    Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
    Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
    Margot NA; Waters JM; Miller MD
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4087-95. PubMed ID: 16982781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziagen (abacavir) approved: caution essential.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY; Vrang L; Oberg B; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abacavir for salvage or intensification.
    Torres G
    GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
    Sluis-Cremer N; Koontz D; Bassit L; Hernandez-Santiago BI; Detorio M; Rapp KL; Amblard F; Bondada L; Grier J; Coats SJ; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3715-9. PubMed ID: 19596885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides.
    Wang J; Jin Y; Rapp KL; Bennett M; Schinazi RF; Chu CK
    J Med Chem; 2005 Jun; 48(11):3736-48. PubMed ID: 15916425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and Antiviral Evaluation of TriPPPro-AbacavirTP, TriPPPro-CarbovirTP, and Their 1',2'-cis-Disubstituted Analogues.
    Weising S; Sterrenberg V; Schols D; Meier C
    ChemMedChem; 2018 Sep; 13(17):1771-1778. PubMed ID: 29943432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Jørgensen LB; Katzenstein TL; Gerstoft J; Mathiesen LR; Pedersen C; Nielsen C
    Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NIH conference. Antiretroviral therapy in AIDS.
    Broder S; Mitsuya H; Yarchoan R; Pavlakis GN
    Ann Intern Med; 1990 Oct; 113(8):604-18. PubMed ID: 1698042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays.
    Zhang J; Rhee SY; Taylor J; Shafer RW
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):439-44. PubMed ID: 15764961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir.
    Van Laethem K; Witvrouw M; Balzarini J; Schmit JC; Sprecher S; Hermans P; Leal M; Harrer T; Ruiz L; Clotet B; Van Ranst M; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 2000 Mar; 14(4):469-71. PubMed ID: 10770556
    [No Abstract]   [Full Text] [Related]  

  • 39. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
    Kessler HA; Johnson J; Follansbee S; Sension MG; Mildvan D; Sepulveda GE; Bellos NC; Hetherington SV
    Clin Infect Dis; 2002 Feb; 34(4):535-42. PubMed ID: 11797183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.
    Kline MW; Blanchard S; Fletcher CV; Shenep JL; McKinney RE; Brundage RC; Culnane M; Van Dyke RB; Dankner WM; Kovacs A; McDowell JA; Hetherington S
    Pediatrics; 1999 Apr; 103(4):e47. PubMed ID: 10103339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.